Where next for Merck?Will it break the triangle pattern formed from Dec 2019?
Not easy to tell but I'm thinking of a bullish breakout. Time will tell.
6MK trade ideas
20 years is a long wait, will Merck regain its glorious days ?Study this article carefully !
From a consumer perspective, if these pills are proven safe and effective with minimal side effects, I am sure the take up rate would be much higher , better still if they can be sold at pharmacies and other distribution outlets for easy access. Jabs take a longer time and the process is much longer as it requires the administration by a qualified staff from the healthcare sector. This takes time on both ends and delay the rates of vaccination to some extent.
Let's wait patiently and see which stock shows a more bullish signs in the coming weeks.
Merck Stocks Have a 25% Growth PotentialToday we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency.
Let’s analyse the chart with the Merck stocks and their upside potential.
When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend. So, if we look at the monthly timeframe chart of Merck stocks we may find an upward trend that started in March 2009. We may also see a consolidation since January 2020 that lasted until September 2021, that is forming a triangle. This figure acts as a continuation sequence of the trend as the upward breakthrough has already been made. The breakthrough occurred on October 1, when the company announced successful clinical trial results of its anti-COVID-19 pill.
This announcement was made a week before and no other news has been announced concerning this. This triangle provides a potential for Merck stocks to go to the $103.50-104 area. So, it is a potential gain of 25-26% from the current price. Moreover, the gap on October 1 is now acting as a key support level. Nevertheless, technically we may have a retest of the upper triangle margin at the $78.50-$79.30 area. But even if this retest does not happen, as it is not always the case, it is worth to consider adding these stocks to the portfolio.
It should be noted that this technical pattern has been forming for several months and we should expect that the upside scenario would be effective for a while still. It may take 2-3 month, or even more, to reach the mentioned targets. However, such long-term technical patterns usually provide a good profit for those who are not looking for a checkered fortune.Merck has made contracts to deliver its pills not only in the United States, but also with other governments that are currently considering purchasing this new medication.
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next.
"Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
$MRK Breaking out of two year accumulation zone into new ATH's.Merck is looking primed for a run into the $90's or higher after breaking 2 years of accumulation on the weekly chart. Ideally I want to see this hold the $84 support level and then bounce back through the all time high's.
There is also huge call flow the past two days. One option chain that is getting some attention is Nov 19 $90 calls.
Morgan Stanley also raised guidance from $88 to $90 and maintained equal-weight on the stock.
Bullish.
Merck & Co: Covid news linked breakout - BullishMerck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Average Analyst Rating : Moderate Buy : Price target : $92
Hedge Fund Trend: ▼ Hedge Funds Decreased Holdings by 8.8M Shares Last Quarter.
Insider Activity : No Meaningful change last quarter
News Sentiment last week: Very Bullish
Technicals : Positive
Merck and Ridgeback Therapeutics Inc.’s experimental oral antiviral treatment is being heralded as a pill with major upside potential in the fight against the COVID-19 pandemic. Malaysia is in talks to procure an experimental antiviral pill developed by Merck & Co for COVID-19 treatment, the health minister said on Saturday.
Fundamental news brought sharp falls for the vaccine cos that have earlier made huge gains, the likes of PFEs and MRNA and others and MRK moved up sharply, breaking the range it was moving. Since its a news related move, more likely a new range would be created and previous resistance maybe difficult of breach.
Most of the stocks that had fallen because of Covid lockdowns showed glimpses of finding investor interest as Airlines, Casinos & Gamings, Crusie Liners all made substantial moves.
From a technical standpoint, its a Bollinger band blast on Daily charts. The candle formation can be tricky, but the weekly candle looks very strong Watch out for price action on Monday, dip buying should be a good strategy. I think another rotation in its way in terms of sector moves, ride this rally and watch out the Covid news regularly.
Merck Announces Positive Top-Line Results from Pivotal Phase 3 TMRK: Merck & Co., Inc.
2021-10-25 06:45:00
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
0026 MRK:xnys - Breakout Strategy | OptionDate : Wednesday 20th October 2021
Time of trade (Malaysia Time) : 23:35
Scanner : Watchlist Breakout
Entry Price : $0.73 (Stock price $80.29)
Shares : 15
TP (Take Profit) : $1.08
SL (Stop Loss) : When mother stock reaches $76.27
*Prices are in $USD
Technique (Long Call/SPV/ SCV /Iron Condor/Long Put etc) : Long Call
Expiry Date : Friday 22 Oct 2021 (2 days)
Option Entry Price : $0.73
Strike Price : $80.00
Delta : 0.58
Contract : 1 (100)
Comments :
- What's on your mind? (What do you think about what you are doing/did?)
No scanner used, but I got this stock from my Keep an eye on list, with BO strategy. There were 3 greens, so I thought it is a convincing breakout. There was a pole too. I gotta sell this fast tho. exp is 2 days.
- How are you feeling? (e.g. Energetic and well. Energetic and serabut? Unpleasant and uneasy? FeelsOkayMan etc...)
Alright, a chart is a chart is a chart.
P.S. Not sure if I am to trade tonight, because the market looks pretty mixed in the start. But now, it seems to be mildly bullish, so I guess I can try trades. + 0.30% avg
- Any distractions on your mind? (Lawan ngan gf monkaS).
Nope.
$MRK: Vaccine KrptoniteInvestors should continue to watch Merck and how it plays out here at the 80 level as their COVID drug treatment is pending approval. I believe the market is absolutely sleeping on the significance of this drug and the kind of impact it will have. A treatment is an absolute game changer provided the politics of COVID do not disrupt innovation, transparency and competition in the market. If Merck's drug is effective at treating COVID this will be disastrous to companies like MRNA, JNJ, DVAX, PFE and NVAX. Currently, we're still sitting at less than a 60% fully vaccinated population, the tightest labor supply in history and a work force petitioning vaccine mandates as was witnessed with Boeing workers in Seattle. This will force lawmakers hands to suspend vaccine mandates indefinitely crashing demand for vaccines in the future. The US population has made their stance and vaccine persuasion will only have a diminishing effect from here on out, so the only option is the option that works for everyone in order to minimize division in the country.
Merck&Co Analysis 05.10.2021Hello Traders,
welcome to this free and educational analysis.
I am going to explain where I think this asset is going to go over the next days/weeks and where I would look for trading opportunities.
If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below.
I would also appreciate, if you would smash that like button and help me to create more free analysis like that.
Thank you for watching and I will see you tomorrow!
Merck is Flying based on the biased perception..!Merck data shows Molnupiravir will decrease mortality and hospitalization which is a good news, but do not forget it does not mean you do not need COVID-19 Vaccine..!
This is only for those who becomes positive for COVID test, while Vaccine is for everyone!
While many people debate about their choice of being vaccinated or not, I would like to show other countries example:
Australia:
No Jab No Pay
is an Australian policy initiative which withholds three state payments – Child Care Benefit, the Child Care Rebate and a portion of the fortnightly Family Tax Benefit part A per child – for parents of children under 20 years of age who are not fully immunized or on a recognized catch-up schedule.
No Jab No Play
is a related policy that disallows unvaccinated children from attending preschool and childcare centres, and imposes fines on childcare centres that admit unvaccinated children. The system allows exemptions for children who cannot be safely vaccinated for medical reasons.
As a doctor I respect patients choice, but when it is about public health things will become a little complicated from ethical point of view!
I got vaccinated as soon as it becomes possible, and asked all my family members to do so. I want to use this opportunity to ask you to get vaccinated and do not pay attention to misinformation.
I published short analysis on MRNA before this news:
Best,
Moshkelgosha
$MRK - that fake out!!This is a perfect example of the manipulation that can occur in the market. They intentionally sold this down below the trend line and massive consolidation since beginning of 2020. It was done right before a massive announcement. It shows the importance of being invested in quality, buying at the right price, and holding through until you find fundamental reasons not to. Trading is dangerous because the technicians and algos know how to mess you up. GLL!!!
MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891
Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
$MRK with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $MRK after a Negative Under reaction following its earnings release placing the stock in drift D
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
